Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 5, 2007, Pages 701-709

  Lee, Christina ^a   Corren, Jonathan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allergic rhinitis; Azelastine hydrochloride; Non Allergic rhinitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BUDESONIDE; CETIRIZINE; CHLORPHENIRAMINE; CHLORPHENIRAMINE MALEATE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; ERYTHROMYCIN; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCABASTINE; LORATADINE; MOMETASONE FUROATE; MONTELUKAST; PLACEBO; TERFENADINE; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST; ZILEUTON; ANTIALLERGIC AGENT; PHTHALAZINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BITTER TASTE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DYSESTHESIA; EPISTAXIS; FATIGUE; HAY FEVER; HEART ARRHYTHMIA; HUMAN; MONOTHERAPY; NAUSEA; NONHUMAN; NOSE DISEASE; PATHOPHYSIOLOGY; PHARYNGITIS; QT PROLONGATION; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SNEEZING; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VASOMOTOR RHINITIS; WEIGHT GAIN; XEROSTOMIA; ANIMAL; BIOAVAILABILITY; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; EXPERT WITNESS; INTRANASAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-ALLERGIC AGENTS; BIOLOGICAL AVAILABILITY; EXPERT TESTIMONY; HUMANS; PHTHALAZINES; RANDOMIZED CONTROLLED TRIALS; RHINITIS;

EID: 34047226673     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.5.701     Document Type: Review

References (45)

1. DYKEWICZ MS, AND FINEMAN S, SKONER DP et al.: Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. (1998) 81:478-518.
2. BOUSQUET J, VAN CAUWENBERGE P: Allergic rhinitis and its impact on asthma (ARIA). J. Allergy Clin. Immunol. (2001) 108(5):S147-S333.
3. RAY NF, BARANIUK JN, THAMER M et al.: Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J. Allergy Clin. Immunol. (1999) 103:401-407.
4. LAFORCE C: Use of nasal steroids in managing allergic rhinitis. J. Allergy Clin. Immunol. (1999) 103:S388-S394.
5. MELTZER EO: Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. Clin. Ther. (2002) 24:942-952.
6. BOUSQUET J, LOCKEY RF, MALLING HJ: WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy (1998) 53(Suppl.):1-42.
7. 1, β, and muscarinic receptor-binding sites. J. Allergy Clin. Immunol. (1989) 83(4):771-776.
8. CIPRANDI G, PRONZATO C, PASALACQUA G et al.: Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J. Allergy Clin. Immunol (1996) 98:1088-1096.
9. 4. Int. Arch. Allergy Appl. Immunol. (1987) 83:284-289.
10. 4 release and production from asthmatic eosinophils. Respir. Res. (1990) 9(2):206-212.
11. BUSSE W, RANDLEY B, SEDGWICK J: The effect of azelastine on neutrophil and eosinophil generation of superoxide. J. Allergy Clin. Immunol. (1989) 83:400-405.
12. UMEKI S: Effects of antiallergic drugs on human neutrophil superoxide-generating NADPH oxidase. Biochem. Pharmacol. (1992) 43:1109-1117.
13. SHIN MH, BAROODY F, PROUD D et al.: The effect of azelastine on the early allergic response. Clin. Exp. Allergy (1992) 22:289-295.
14. NIEBER K, BAUMGARTEN C, RATHSACK R et al.: Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin. Exp. Allergy (1993) 23:69-71.
15. YONEDA K, YAMAMOTO T, UETA E, OSAKI T: Suppression by azelastine hydrochloride of NFκB activation involved in generation of cytokines and nitric oxide. Jpn. J. Pharmacol. (1997) 73:145-153.
16. RIETHMULLER-WINZEN H, PETER G et al.: Tolerability, pharmacokinetics and dose linearity of azelastine hydrochloride in healthy subjects. Arzneimittelforschung (1994) 44:1136-1140.
17. PETER G, ROMEIS P, BORBE HO, BUKER KM et al.: Tolerability and pharmacokinetics of single and multiple doses of azelastine hydrochloride in elderly volunteers. Arzeimittelforschung (1995) 45(5):576-581.
18. SALE M, LYNESS W, PERHACH J, WOOSLEY R, ROSENBERG A: Lack of effect of coadministration of erythromycin with azelastine on pharmacokinetic or ECG parameters. Ann. Allergy Asthma Immunol. (1996) 76: Abstr. 91.
19. MORGANROTH J, PERHACH JL, LYNESS W et al.: Lack of effect of azelastine alone and coadministered with ketaconazole on electrocardiographic parameters. J. Allergy Clin. Immunol. (1995) 95:Abstr. 282.
20. CHAND N, PILLAR J, DIAMANTIS W, PERHACH JL JR, SOFIA RD: Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: implications for its mode of action. Eur J. Pharmacol. (1983) 96(3-4):227-233.
21. LITTLE MM, CASALE TB: Azelastine inhibits IgE-mediated human basophile histamine release. J. Allergy Clin. Immunol. (1989) 83(5):862-865.
22. GOLDEN MP, GLEASON MM, TOGIAS A: Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin. Exp. Allergy (2006) 36(6):689-703.
23. CHAND N, NOLAN K, DIAMANTIS: Inhibition of leukotriene (SRS-A)-mediated acute lung anaphylaxis by azelastine in guinea pigs. Allergy (1986) 41(7):473-478.
24. RAJAKULASINGAM K, POLOSA R, CHURCH MK et al.: Kinins and rhinitis. Clin. Exp. Allergy (1992) 22:734-740.
25. ITO H, NAKAMURA Y, TAKAGI S, SAKAI K: Effects of azelastine on the level of serum interleukin-4 and soluble CD23 antigen in the treatment of nasal allergy. Arzneimittelforschung (1998) 48:1143-1147.
26. BECK G, MANSUR A, AFZAL M et al.: Effect of azelastine nasal spray on mediators of inflammation in patients with seasonal allergic rhinitis (SAR). Presented at American Academy of Allergy Asthma, and Immunology 56th Annual Meeting. CA, USA (3-8 March 2000).
27. WEILER JM, MELTZER EO, BENSON PM, WEILER K, WIDLITZ MD, FREITAG J: A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J. Allergy Clin. Immunol. (1994) 94:972-980.
28. MELTZER EO, WEILER JM, DOCKHORN RJ, WIDLITZ MD, FREITAG JJ: Azelastine nasal spray in the management of seasonal allergic rhinitis. Ann. Allergy (1994) 72:354-359.
29. HORAK F, ZIEGLMAYER UP, ZIEGLMAYER R et al.: Azelastine nasal spray and desloratadine tablets in pollen induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr. Med. Res. Opin. (2006). 22(1):151-157.
30. BAUMGARTEN CR, PETZOLD U, DOKIE D et al.: Modification of allergen induced symptoms and mediator release by intranasal azelastine. J. Pharmacol. Ther. (1994) 3:43-51.
31. STORMS WW, PEARLMAN DS, CHERVINSKY P et al.: Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J. (1994) 73:382-394.
32. RATNER PH, FINDLAY SR, HAMPEL F, VAN BAVEL J, WIDLITZ MD, FREITAG JJ: A double blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J. Allergy Clin. Immunol. (1994) 94:818-825.
33. LAFORCE C, DOCKHORN RJ, PRENNER BM et al.: Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. (1996) 76:181-188.
34. CIPRANDI G, RICCA V, PASSALACQUA G et al.: Seasonal rhinitis and azelastine: long- or short-term treatment? J. Allergy Clin. Immunol. (1997) 99:301-307.
35. BERGER WE, WHITE MV, THE RHINITIS STUDY GROUP: Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann. Allergy Asthma Immunol. (2003) 91:205-211.
36. LAFORCE CF, CORREN J, WHEELER WJ, BERGER WE, THE RHINITIS STUDY GROUP: Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann. Allergy Asthma Immunol. (2004) 93:154-159.
37. CORREN J, STORMS WW, BERNSTEIN J et al.: Effectiveness of azelastine nasal spray compared to oral cetirizine in patients with seasonal allergic rhinitis. Clin. Ther. (2005) 27:543-553.
38. BERGER W, HAMPEL F Jr., BERNSTEIN J et al.: Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. (2006) 97:375-381.
39. FALSER N, WOBER W, RAHLFS VW, BAEHRE M: Comparative efficacy and safety of azelastine and levocabastine nasal sprays in patients with seasonal allergic rhinitis. Arzeimittelforschung (2001) 51(5):387-393.
40. WANG D, SMITZ J, DE WAELE M, CLEMENT P: Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. Int. Arch. Allergy Immunol. (1997) 114:185-192.
41. BANOV C, LIEBERMAN P: Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann. Allergy Asthma Immunol. (2001) 86:28-35.
42. LIEBERMAN P, KALINER MA, WHEELER WJ: Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Curr. Med. Res. Opin. (2005) 21:611-618.
43. KANEKO T, KITAHARA A, OZAKI S et al.: Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system. Arzeimittelforschung (1981) 31:1206-1212.
44. KAKIUCHI M, OHASHI T, TANAKA K et al.: Central nervous system effects of the novel antiallergic agent HSR-609 and typical antiallergic agents using behavioral and electroencephalographic analyses in dogs. Nihon Shinkei Seishin Yakurigaku Zasshi. (1998) 18(5):189-199.
45. BRONSKY FA, MELTZER EO, PERHACH JL et al.: Cardiac safety of azelastine following 8 weeks of intra-nasal administration [abstract]. J. Allergy Clin. Immunol. (1997) 99(Pt 2):S445.